Bernstein initiated coverage of BridgeBio (BBIO) with an Outperform rating and $94 price target The firm believes expectations for Attruby are reasonable in the near-term and “arguably too high” in the long term. However, consensus estimates for infigratinib and encaleret have upside, the analyst tells investors in a research note.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBIO:
- BridgeBio Pharma: Buy Rating Backed by Promising Drug Pipeline and Strategic Market Positioning
- BridgeBio presents BBO-10203 data at San Antonio Breast Cancer Symposium
- BridgeBio price target raised to $84 from $76 at Wells Fargo
- BridgeBio presents data from ATTRibute-CM study on acoramidis
- BridgeBio price target raised to $77 from $76 at JPMorgan